Ascendis Pharma ASND Stock
Ascendis Pharma Price Chart
Ascendis Pharma ASND Financial and Trading Overview
| Ascendis Pharma stock price | 228.03 USD |
| Previous Close | 227.31 USD |
| Open | 227.63 USD |
| Bid | 207.46 USD x 200 |
| Ask | 245.84 USD x 200 |
| Day's Range | 225.2 - 228.91 USD |
| 52 Week Range | 186.05 - 282.15 USD |
| Volume | 641.43K USD |
| Avg. Volume | 646.66K USD |
| Market Cap | 14.99B USD |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | 17.760717 |
| EPS (TTM) | 13.05 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 307.36 USD |
ASND Valuation Measures
| Enterprise Value | 14.6B USD |
| Trailing P/E | 17.760717 |
| Forward P/E | 20.895988 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 14.321287 |
| Price/Book (mrq) | 9.186669 |
| Enterprise Value/Revenue | 13.947 |
| Enterprise Value/EBITDA | 55.428 |
Trading Information
Ascendis Pharma Stock Price History
| Beta (5Y Monthly) | N/A |
| 52-Week Change | 7.81% |
| S&P500 52-Week Change | 14.15% |
| 52 Week High | 282.15 USD |
| 52 Week Low | 186.05 USD |
| 50-Day Moving Average | 249.19 USD |
| 200-Day Moving Average | 235.49 USD |
ASND Share Statistics
| Avg. Volume (3 month) | 646.66K USD |
| Avg. Daily Volume (10-Days) | 895.54K USD |
| Shares Outstanding | 65.8M |
| Float | 65.64M |
| Short Ratio | 6.31 |
| % Held by Insiders | 0.77% |
| % Held by Institutions | 104.04% |
| Shares Short | 3.96M |
| Short % of Float | 7.12% |
| Short % of Shares Outstanding | 6.01% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2025 |
| Most Recent Quarter (mrq) | June 30, 2026 |
| Next Fiscal Year End | December 31, 2026 |
Profitability
| Profit Margin | 70.84% |
| Operating Margin (ttm) | 64.97% |
| Gross Margin | 91.29% |
| EBITDA Margin | 25.16% |
Management Effectiveness
| Return on Assets (ttm) | 9.58% |
| Return on Equity (ttm) | 118.78% |
Income Statement
| Revenue (ttm) | 1.05B USD |
| Revenue Per Share (ttm) | 16.89 USD |
| Quarterly Revenue Growth (yoy) | 114.70% |
| Gross Profit (ttm) | 955.89M USD |
| EBITDA | 263.45M USD |
| Net Income Avi to Common (ttm) | 741.76M USD |
| Diluted EPS (ttm) | 12.83 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 812.26M USD |
| Total Cash Per Share (mrq) | 12.37 USD |
| Total Debt (mrq) | 450.07M USD |
| Total Debt/Equity (mrq) | 31.33 USD |
| Current Ratio (mrq) | 2.991 |
| Book Value Per Share (mrq) | 24.804419 |
Cash Flow Statement
| Operating Cash Flow (ttm) | 349.51M USD |
| Levered Free Cash Flow (ttm) | 12.77M USD |
Profile of Ascendis Pharma
| Country | United States |
| State | N/A |
| City | Hellerup |
| Address | Tuborg Boulevard 12 |
| ZIP | 2900 |
| Phone | 45 70 22 22 44 |
| Website | https://ascendispharma.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 1189 |
Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is based in Hellerup, Denmark.
Q&A For Ascendis Pharma Stock
What is a current ASND stock price?
Ascendis Pharma ASND stock price today per share is 228.03 USD.
How to purchase Ascendis Pharma stock?
You can buy ASND shares on the Tech Market Large exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Ascendis Pharma?
The stock symbol or ticker of Ascendis Pharma is ASND.
Which industry does the Ascendis Pharma company belong to?
The Ascendis Pharma industry is Biotechnology.
How many shares does Ascendis Pharma have in circulation?
The max supply of Ascendis Pharma shares is 65.8M.
What is Ascendis Pharma Price to Earnings Ratio (PE Ratio)?
Ascendis Pharma PE Ratio is 17.47356200 now.
What was Ascendis Pharma earnings per share over the trailing 12 months (TTM)?
Ascendis Pharma EPS is 13.05 USD over the trailing 12 months.
Which sector does the Ascendis Pharma company belong to?
The Ascendis Pharma sector is Healthcare.
Ascendis Pharma ASND included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
|
|
{{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
US Tech Composite
IXIC
US
|
27477.31 USD — |
+1.05
|
7.04B USD — | 27223.49 USD — | 27544.06 USD — | — - | 7.04B USD — |
|
US Tech Global Select Market Com
NQGS
US
|
13524.02 USD — |
+1.07
|
— — | 13397.04 USD — | 13557.29 USD — | — - | — — |
|
US Tech Biotechnology
NBI
US
|
7022.12 USD — |
+1.07
|
— — | 6892.36 USD — | 7043.1 USD — | — - | — — |
|
US Tech Health Care
IXHC
US
|
1320 USD — |
+1.33
|
— — | 1298.21 USD — | 1322.56 USD — | — - | — — |
|
US Tech Composite Total Return
XCMP
US
|
33942.38 USD — |
+1.05
|
— — | 33628.84 USD — | 34024.84 USD — | — - | — — |
|
Stlmt ID US Tech Biotechnology
NBX
US
|
4000.62 USD — |
-1.26
|
— — | 3927.42 USD — | 4148.65 USD — | — - | — — |
- {{ link.label }} {{link}}
